- Lobbying
- Lobbying by Centerline Biomedical
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Elizabeth Powell | Legislative Director for Rep. Jim Langevin 2001-2002 and Legislative Director/Legislative Assistant for Rep. Juanita Millender-McDonald 1997-2001 |
John Richter | Legislative Assistant for Rep. Michelle Lujan Grisham (2014-2017) and Legislative Aide/Legislative Correspondent for Sen. Robert P. Casey, Jr. (2010-2014) |
Christopher Cooper | Chief Appropriations Counsel,Chief of Staff,Legislative Director,Senior Legislative Assistant,Legislative Assistant for David Joyce (2013-2023) & Legislative Assistant/ Correspondent,Staff Assistant,Legislative Intern for Steven LaTourette(2011-2013) |
Greg Kapcar | n/a |
Aditya Girish | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Termination
Q3 Report
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues
Registration
Issue(s) they said they’d lobby about: Support for technology to improve endovascular surgery outcomes..
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate